EKBI Business Intelligence Beautiful Information

< **September 14** > **SCORES**

RESET

Trust Commentary

Total activity in September 2014 has over performed in every POD, with the exception of Outpatient Follow Up's, which marginally under performed at -0.6%. This is in contrast to August, which under performed in most areas and against the YTD trend. Areas of significance include Primary Care Referrals (+9%), regular Day Attenders (+13%) and Elective Inpatient activity (+7%). A&E, following a period of under performance, has over performed by +3% in September. This trend looks to continue in October, where it's current in-month variance is 14.5%.

The "PbR Managed Contract" continues to mirror this trend in month and at an overall level YTD. The "Other PbR Contract" is under-performing in month for Inpatient activity but, YTD, continues to over perform. YTD over performance is still being driven by Outpatients, in particular Maxillo Facial.

Primary Care Referrals, at a Corporate level, are over performing by 9% in month, 6.4% YTD position. With the exception of Clinical Support (-10 against plan), all Division's have shown increases in-month with key specialties being T&O +35%, Maxillo Facial +18% and General Surgery +21%.

Inpatient Elective activity, following under performance, has over perfomed in month by 7%. Importantly this also shows a 8.5% increase against activity levels seen last year, most noticeably in UC&LTC. While the Surgical division remain slightly over plan, the biggest drivers are Specialist and UC&LTC divisons. Paediatrics increases are again due to the coding changes and Cardiology has also seen a higher than expected increase which is being investigated further by the division.

The RTT resilience funding has helped drive an over performance against our contract plan, particularly within T&O and General Surgery, and this is likely to improve the position further over the coming months.

Key National Targets

Monitor

Domain	Metric Name	MTD	QTD	YTD
Patient Safety	Cases of CDiff (Cumulative)	1	1	1
Effectiveness	A&E: Time in A&E (%)	1	1	1
	Cancer: 2WW (All)	5	5	5
	Cancer: 2WW (Breast)	1	1	1
	Cancer: 31D (Diag - Treat)	5	5	5
	Cancer: 31D (2nd Treat - Surg)	1	1	5
	Cancer: 31D (Drug)	5	5	5
Access & Productivity	Cancer: 62D (GP Ref)	1	1	1
	Cancer: 62D (Screening Ref)	1	1	5
	RTT: Admitted (%)	1	1	1
	RTT: Non Admitted (%)	5	5	5
	RTT: Incompletes (%)	5	5	5
	DM01: Diagnostic Waits	1	1	1

Internally Monitored Indicators

Quality

Domain	Metric Name	MTD	QTD	Y[illegible]
	HSMR			[illegible]
Patient Safety	Crude Mortality EL (per 1,000)	5	5	[illegible]
	Crude Mortality NEL (per 1,000)	5	5	[illegible]
Effectiveness	Readmissions: EL dis. 30d (12M%)	4	4	[illegible]
	Readmissions: NEL dis 30d (12M%)	5	3	[illegible]

Activity (% Variance to Plan)

Domain	Metric Name	MTD	QTD	Y[illegible]
	Referrals - Primary Care	1	1	[illegible]
	Referrals - Total	1	1	[illegible]
Activity	A&E Attendances	2	4	[illegible]
	Outpatient Appointments	5	3	[illegible]
	Elective Admissions	1	3	[illegible]
	Non-Elective Admissions	2	4	[illegible]
Access & Productivity	DNA Rate: New	4	4	[illegible]
	DNA Rate: Follow-Up	4	5	[illegible]

Efficiency

Domain	Metric Name	MTD	QTD	Y[illegible]
	Clinical Time Worked (%)		2	[illegible]
Valuing People	Unplanned Agency Expense	5	1	[illegible]
	Appraisal Quality	5	5	[illegible]
	Training Plans (Quarterly)	5	5	[illegible]
	Sickness (%)	3	4	[illegible]
	BADS	5	5	[illegible]
Access & Productivity	Theatres: Session Utilisation (%)	4	4	[illegible]
	Non Clinical Cancellations (%)	5	5	[illegible]
	Non-Clinical Canx Breaches (%)	5	3	[illegible]

East Kent Hospitals University NHS Foundation Trust

Overview of Trust Financial Performance

Trust Key Performance Indicators (£m)	Annual target	Year to Date Plan	Year to Date Actual
Total operating income	532.5	263.4	**261.3**
CIP savings	26.8	11.5	**9.2**
EBITDA	30.1	14.4	**12.1**
I&E net surplus	(0.9)	0.8	**(1.2)**
Cash balance	27.4	28.9	**31.8**

Monitor Continuity of Service Risk Rating	Annual target	Year to date Plan	Year to Date Actual
Continuity of Service Risk Rating	4	4	**3.5**

The financial statements and summaries in this report are prepared for internal performance monitoring purposes and have not been audited. The Trust accepts no liability for any decisions made by persons external to the Trust based on this information.

Note: Detailed financial tables are on page 3

Statement of Comprehensive Income (Income and Expenditure)
The Income and Expenditure deficit for September is £(0.6)m, a favourable variance of £0.2m. For the YTD the position is £(1.2)m against a surplus plan of £0.8m, resulting in an overall adverse variance of £(2)m.
- The subsidiary company (Healthex Limited which runs the Spencer Wing at QEQMH) is reporting a YTD surplus of £0.3m to September which is above plan and not included in the above position.

Improvement Programme
The Efficiency Programme for the financial year amounts to £26.8m as set out in the Financial Strategy. The month 6 CIP target was missed by £(0.5)m and is adverse to plan by £(2.3)m year to date. This is mainly due to adverse performance in corporate savings schemes.(see page 4).

Statement of Financial Position (Balance Sheet)
The Trust Statement of Financial Position and Cash summary are set out on page 3.
- The Trust has £17.5m of net current assets at the end of September and total net assets of £317.2m. The closing cash balance of £31.8m is £2.9m favourable to plan for the month, mainly due to the payments from Health Education England for Quarter 2, which were higher than planned in July and August but on plan for the Quarter. Receipts from the EK CCGs were £1.4m lower in September due partially to a reduction in high cost drugs payments (passthrough costs) and and agreed changes to the contract values reflective of 2014/15 agreed plans. Creditor payments were slightly lower than the previous month and also just below plan Other Payments include the half yearly repayment of PDC. The position remains ahead of plan, mainly due to due to SCG receipts relating to 2013/14, higher VAT reclaims and the delay in the start of KPP and SACP.

Capital Expenditure Programme
The table on page 3 summarises £13.7m of expenditure on capital projects in the year so far.

Financial Performance Indicators
The Trust is achieving the rating of 3.5 under Monitor's Continuity of Service Risk Rating.

Identified Financial Risks
The Trust has not recovered the adverse YTD EBITDA performance which continues to be adverse to plan.
The risk of shortfalls in the delivery of Commissioning Intentions and CIPs.
The Trust has been placed in Special Measures by Monitor.
The settlement of the 2013/14 contracts with East Kent CCGs remains outstanding. Partial provisions were made in the 2013/14 accounts but are unlikely to miigate the full volume now challenged.

How financial risks are being addressed
The following actions are in place:
- Savings plans that cross divisional boundaries have been adjusted to reflect operational challenges due to high demand for Trust services. With support from Corporate functions and the Executive Team, focus remains on Divisions implementing agreed actions to improve delivery of CIP schemes.